Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lineage Cell TherapeuticsLCTX -0.90%61 Equity-to-Asset is 0.57 as of Jun. 2026, which is 30% below its 10-year median of 0.82. GuruFocus rates LCTX with a GF Score™ of 61/100 and a GF Value™ of $1.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, Lineage Cell Therapeutics ranks worse than 61.32% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lineage Cell Therapeutics Equity-to-Asset Related Terms
Lineage Cell Therapeutics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LCTX vs IVVD, ALXO, AVXL: Equity-to-Asset Comparison
For the Biotechnology subindustry, Lineage Cell Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lineage Cell Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (LCTX) has a Equity-to-Asset of 0.57 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lineage Cell Therapeutics and its competitors. This is 30% below median its historical median of 0.82. Over the past decade, Lineage Cell Therapeutics' Equity-to-Asset has ranged from 0.25 to 0.97. According to the industry distribution chart, Lineage Cell Therapeutics ranks #867 out of 1414 companies in the Biotechnology industry, placing it in the top 61.3%.
Is Lineage Cell Therapeutics' Equity-to-Asset too high?
Lineage Cell Therapeutics' current Equity-to-Asset of 0.57 is 30% below median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 0.97. The Biotechnology industry median Equity-to-Asset is 0.69. Lineage Cell Therapeutics' value of 0.57 is 17.4% below this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #867 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lineage Cell Therapeutics has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Equity-to-Asset compare to IVVD and ALXO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #867 out of 1414 companies for Equity-to-Asset. This places Lineage Cell Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Lineage Cell Therapeutics' value of 0.57 is 17.4% below this benchmark. Historically, Lineage Cell Therapeutics' own Equity-to-Asset has ranged from 0.25 to 0.97 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.69, Lineage Cell Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current Equity-to-Asset of 0.57 is 17.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current Equity-to-Asset is 0.57, which is 30% below median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.17, compared to a current price of $1.10 — trading 6% below its estimated fair value. The current Equity-to-Asset is 0.57, which is 30% below median its 10-year median of 0.82 and 17.4% below the Biotechnology industry median of 0.69. Lineage Cell Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Equity-to-Asset is 0.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.10 is trading 6% below its estimated GF Value™ of $1.17.
GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.
Key valuation signals for LCTX:
Equity-to-Asset: 0.57 (30% below median its 10-year median of 0.82)
GF Value™: $1.17 vs. price of $1.10 (6% below fair value)
Industry Position: 17.4% below the Biotechnology median (#867 of 1414)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
61GF Score
Get the complete analysis for LCTX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
